Fibrinolysin, human
As of the edition of 20 October 2026, Fibrinolysin, human is a drug: marketed, first approved in 1964 (US); acts on FGA, FGB and FGG; US protection ended in 1976.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1964
- Kind
- Unknown
- Brand name
- Elase-chloromycetin
- First approved
- 1 April 1964 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 5, 2 stopped early
- Disease areas
- Heart and blood vessels; Nervous system
US protection
US protection ended in 1976.
US protection ended in 1976, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Pfizer. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 2 | 0 | 2 |
| All trials | 5 |